Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy

October 25, 2022

https://www.globenewswire.com/news-release/2022/10/25/2540648/0/en/Applied-Therapeutics-Announces-Full-Enrollment-in-the-Registrational-Phase-3-ARISE-HF-Trial-of-AT-001-in-Diabetic-Cardiomyopathy.html

NEW YORK, Oct. 25, 2022 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced full enrollment in the Phase 3 registrational ARISE-HF trial, studying AT-001, a selective Aldose Reductase inhibitor, in patients with Diabetic Cardiomyopathy (DbCM).

Read more at globenewswire.com

Related news for (APLT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.